# Gilead Sciences (GILD) total liabilities: $36.41B in 2025

URL: https://funkfolio.com/stock/GILD/total-liabilities

> Gilead Sciences (GILD) total liabilities were $36.41B at the end of fiscal 2025, down 8.4% from fiscal 2024. Year-by-year chart and table.

---

## Gilead Sciences (GILD) total liabilities

**Total liabilities · fiscal 2025:** $36.41B at Dec 31, 2025

Gilead Sciences (GILD) had total liabilities of $36.41B at the end of fiscal 2025 (December 31, 2025). That is 8.4% lower than the $39.75B of fiscal 2024. Figures as of 18 Nov 2026, 20:29 UTC, from the company's filings with the SEC and Yahoo Finance.

### Key facts

- **Total liabilities, fiscal 2025:** $36.41B
- **Change on fiscal 2024:** −8.4%
- **Highest on record:** $41.96B fiscal 2022
- **Lowest on record:** $36.41B fiscal 2025
- **Fiscal years on record:** 4 2022–2025

Figures as of 18 Nov 2026, 20:29 UTC. Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

### Gilead Sciences total liabilities, in more detail

Across the 4 fiscal years on record (2022–2025), the highest was $41.96B in fiscal 2022 and the lowest $36.41B in fiscal 2025.

### Total liabilities by fiscal year

### Gilead Sciences total liabilities, year by year

Gilead Sciences (GILD) total liabilities by fiscal year

| Fiscal year | Total liabilities | Change | Year ended |
| --- | --- | --- | --- |
| 2025 | $36.41B | 8.4% down | Dec 31, 2025 |
| 2024 | $39.75B | 0.9% up | Dec 31, 2024 |
| 2023 | $39.38B | 6.2% down | Dec 31, 2023 |
| 2022 | $41.96B | — | Dec 31, 2022 |

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

### How it is calculated

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.

### How to read it

It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.

### Total liabilities at health care companies of similar size

Total liabilities of Gilead Sciences and comparable companies

| Company | Total liabilities | Fiscal year |
| --- | --- | --- |
| [Thermo Fisher Scientific TMO](https://funkfolio.com/stock/TMO/total-liabilities) | $56.81B | 2025 |
| [Amgen AMGN](https://funkfolio.com/stock/AMGN/total-liabilities) | $81.93B | 2025 |
| Gilead Sciences GILD | $36.41B | 2025 |
| [Abbott Laboratories ABT](https://funkfolio.com/stock/ABT/total-liabilities) | $33.94B | 2025 |
| [Novo Nordisk NVO](https://funkfolio.com/stock/NVO/total-liabilities) | DKK 348.86B | 2025 |
| [Pfizer PFE](https://funkfolio.com/stock/PFE/total-liabilities) | $121.39B | 2025 |

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

### Gilead Sciences, figure by figure

- [Gilead Sciences market cap](https://funkfolio.com/stock/GILD/market-cap)
- [Gilead Sciences revenue](https://funkfolio.com/stock/GILD/revenue)
- [Gilead Sciences earnings](https://funkfolio.com/stock/GILD/earnings)
- [Gilead Sciences earnings per share (EPS)](https://funkfolio.com/stock/GILD/eps)
- [Gilead Sciences P/E ratio](https://funkfolio.com/stock/GILD/pe-ratio)
- [Gilead Sciences P/S ratio](https://funkfolio.com/stock/GILD/ps-ratio)
- [Gilead Sciences P/B ratio](https://funkfolio.com/stock/GILD/pb-ratio)
- [Gilead Sciences free cash flow](https://funkfolio.com/stock/GILD/free-cash-flow)
- [Gilead Sciences operating margin](https://funkfolio.com/stock/GILD/operating-margin)
- [Gilead Sciences dividend](https://funkfolio.com/stock/GILD/dividend)
- [Gilead Sciences shares outstanding](https://funkfolio.com/stock/GILD/shares-outstanding)
- [Gilead Sciences total debt](https://funkfolio.com/stock/GILD/total-debt)
- [Gilead Sciences cash on hand](https://funkfolio.com/stock/GILD/cash)
- [Gilead Sciences total assets](https://funkfolio.com/stock/GILD/total-assets)
- [Gilead Sciences net assets (shareholders' equity)](https://funkfolio.com/stock/GILD/net-assets)
- [Gilead Sciences return on equity (ROE)](https://funkfolio.com/stock/GILD/roe)
- [Gilead Sciences return on invested capital (ROIC)](https://funkfolio.com/stock/GILD/roic)

[Gilead Sciences (GILD) overview: price, valuation and scorecard](https://funkfolio.com/stock/GILD) [All health care companies by market value](https://funkfolio.com/companies/sector/health-care)

### Gilead Sciences total liabilities: questions and answers

**How large are Gilead Sciences's total liabilities?**

Gilead Sciences (GILD) had total liabilities of $36.41B at the end of fiscal 2025 (December 31, 2025). That is 8.4% lower than the $39.75B of fiscal 2024.

**What are the highest and lowest total liabilities figures on record for Gilead Sciences?**

Across the 4 fiscal years on record (2022–2025), the highest was $41.96B in fiscal 2022 and the lowest $36.41B in fiscal 2025.

**How is Gilead Sciences's total liabilities calculated?**

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Gilead Sciences it is on record here for 4 fiscal years, 2022 to 2025.

Fiscal years are named for the calendar year they end in.

### Learn: total liabilities

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Market cap vs enterprise value: what is the difference?](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

  Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.

### Cite this page

Funkfolio, “Gilead Sciences (GILD) total liabilities”, data as of 18 November 2026. https://funkfolio.com/stock/GILD/total-liabilities

Underlying data: the company's filings with the SEC and Yahoo Finance.
